Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.09 -0.48% -0.01
RIGL closed down 0.48 percent on Friday, January 18, 2019, on 3.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RIGL trend table...

Date Alert Name Type % Chg
Jan 18 New Downtrend Bearish 0.00%
Jan 18 Volume Surge Other 0.00%
Jan 18 Stochastic Reached Oversold Weakness 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 NR7 Range Contraction -0.48%
Jan 16 MACD Bearish Signal Line Cross Bearish -2.34%
Jan 16 180 Bearish Setup Bearish Swing Setup -2.34%
Jan 14 Wide Bands Range Expansion -1.88%

Older signals for RIGL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Is RIGL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.71
52 Week Low 1.96
Average Volume 2,319,428
200-Day Moving Average 3.0705
50-Day Moving Average 2.5644
20-Day Moving Average 2.243
10-Day Moving Average 2.243
Average True Range 0.157
ADX 25.58
+DI 13.1262
-DI 26.3206
Chandelier Exit (Long, 3 ATRs ) 2.299
Chandelier Exit (Short, 3 ATRs ) 2.431
Upper Bollinger Band 2.481
Lower Bollinger Band 2.005
Percent B (%b) 0.18
BandWidth 21.221578
MACD Line -0.1258
MACD Signal Line -0.1204
MACD Histogram -0.0054
Fundamentals Value
Market Cap 259.98 Million
Num Shares 124 Million
EPS -0.68
Price-to-Earnings (P/E) Ratio -3.07
Price-to-Sales 45.70
Price-to-Book 6.79
PEG Ratio -0.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.30
Resistance 3 (R3) 2.31 2.25 2.27
Resistance 2 (R2) 2.25 2.20 2.25 2.25
Resistance 1 (R1) 2.17 2.16 2.14 2.16 2.24
Pivot Point 2.11 2.11 2.10 2.11 2.11
Support 1 (S1) 2.03 2.06 2.00 2.02 1.94
Support 2 (S2) 1.97 2.02 1.97 1.93
Support 3 (S3) 1.89 1.97 1.92
Support 4 (S4) 1.88